Physician profile
David Ryan
NPI 1134130131
$1,318.53
in general payments reported to CMS, 2019-2025
22 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $136 · 2021: $286 · 2022: $22.24 · 2023: $94.14 · 2024: $317 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $294.76 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $139.50 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.74 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $117.98 | 2019-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $93.21 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $77.82 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $73.11 | 2019-2024 | |
| Indivior INC. | $55.26 | 2021 | |
| Abbvie INC. | $52.01 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.22 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $38.86 | 2021 | |
| Amarin Pharma, INC. | $30.23 | 2019-2020 | |
| Abbott Laboratories | $23.79 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $22.84 | 2019-2020 | |
| Astellas Pharma US INC | $21.42 | 2024 | Veozah |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $19.96 | 2019 | |
| Lilly USA, LLC | $19.82 | 2024 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $16.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.86 | 2019 | |
| Gilead Sciences, INC. | $15.21 | 2019 | |
| Corcept Therapeutics | $14.55 | 2024 | Korlym |
| Organon LLC | $5.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.